Review



hasmir 107  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress hasmir 107
    Hasmir 107, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/HY-R00282/hsa-miR-145-5p+mimic/pm42258751-239-41-49
    Average 94 stars, based on 3 article reviews
    hasmir 107 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Negative Control:

    Article Title: Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy
    Article Snippet: BMSCs (1 × 10 4 cells/well) were suspended in serum-free medium and seeded in the upper chamber of a 24-well transwell plate with an 8-μm pore filter (Corning, NewYork, USA), with BEAS-2B cells containing 10% serum medium in the lower chamber. .. Three experimental settings were as follows: (1) The negative control was transfected (BMSCs-NC + BEAS-2B); (2) miR-145-5p mimics was transfected (BMSCs-mimics + BEAS-2B); (3) The overexpressed BMSCs were pretreated with GW4869 (10μM, MedChemExpress, New Jersey, USA) for 24 h (BMSCs-mimics + GW4869 + BEAS-2B). ..

    Article Title: Endoplasmic reticulum-resident α-glucosidase II drives non-small cell lung cancer progression via regulation of secretory glycoproteins.
    Article Snippet: .. The resulting samples were subjected to WB analysis. miRNAs screening and Luciferase reporter assay. miRNA mimics were purchased from Thermo Fisher Scientific, including mirVana miRNA Mimic Negative Control #1 (catalog 4464058), hsa-miR-193a-5p (MC11786), hsa-miR-133a-3p (MC10413), and hsa-miR-483-3p (MC124780). miRNA mimics including hasmiR-107 (HY-R00057) and has-miR-145-5p (HY-R00282) were purchased from medChemExpress. ..

    Article Title: Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy.
    Article Snippet: BMSCs (1 × 104 cells/well) were suspended in serum-free medium and seeded in the upper chamber of a 24-well transwell plate with an 8-μm pore filter (Corning, NewYork, USA), with BEAS-2B cells containing 10% serum medium in the lower chamber. .. Three experimental settings were as follows: (1) The negative control was transfected (BMSCs-NC + BEAS-2B); (2) miR-145-5p mimics was transfected (BMSCs-mimics + BEAS-2B); (3) The overexpressed BMSCs were pretreated with GW4869 (10μM, MedChemExpress, New Jersey, USA) for 24 h (BMSCs-mimics + GW4869 + BEAS-2B). ..

    Article Title: Circular RNA PTPN4 Contributes to Blood-Brain Barrier Disruption during Early Epileptogenesis.
    Article Snippet: .. The miR-145a-5p mimics (HY-R00282), miRNA mimics negative Control (HY-R04602), miR-145a-5p inhibitor (HY-RI00282), and miRNA inhibitor negative Control (HY-RI04602) were purchased from Med Chem Express (MCE). ..

    Article Title: Circular RNA PTPN4 Contributes to Blood‐Brain Barrier Disruption during Early Epileptogenesis
    Article Snippet: .. The miR‐145a‐5p mimics (HY‐ R00282 ), miRNA mimics negative Control (HY‐ R04602 ), miR‐145a‐5p inhibitor (HY‐RI00282), and miRNA inhibitor negative Control (HY‐RI04602) were purchased from Med Chem Express (MCE). ..

    Transfection:

    Article Title: Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy
    Article Snippet: BMSCs (1 × 10 4 cells/well) were suspended in serum-free medium and seeded in the upper chamber of a 24-well transwell plate with an 8-μm pore filter (Corning, NewYork, USA), with BEAS-2B cells containing 10% serum medium in the lower chamber. .. Three experimental settings were as follows: (1) The negative control was transfected (BMSCs-NC + BEAS-2B); (2) miR-145-5p mimics was transfected (BMSCs-mimics + BEAS-2B); (3) The overexpressed BMSCs were pretreated with GW4869 (10μM, MedChemExpress, New Jersey, USA) for 24 h (BMSCs-mimics + GW4869 + BEAS-2B). ..

    Article Title: Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy.
    Article Snippet: BMSCs (1 × 104 cells/well) were suspended in serum-free medium and seeded in the upper chamber of a 24-well transwell plate with an 8-μm pore filter (Corning, NewYork, USA), with BEAS-2B cells containing 10% serum medium in the lower chamber. .. Three experimental settings were as follows: (1) The negative control was transfected (BMSCs-NC + BEAS-2B); (2) miR-145-5p mimics was transfected (BMSCs-mimics + BEAS-2B); (3) The overexpressed BMSCs were pretreated with GW4869 (10μM, MedChemExpress, New Jersey, USA) for 24 h (BMSCs-mimics + GW4869 + BEAS-2B). ..

    Western Blot:

    Article Title: Endoplasmic reticulum-resident α-glucosidase II drives non-small cell lung cancer progression via regulation of secretory glycoproteins.
    Article Snippet: .. The resulting samples were subjected to WB analysis. miRNAs screening and Luciferase reporter assay. miRNA mimics were purchased from Thermo Fisher Scientific, including mirVana miRNA Mimic Negative Control #1 (catalog 4464058), hsa-miR-193a-5p (MC11786), hsa-miR-133a-3p (MC10413), and hsa-miR-483-3p (MC124780). miRNA mimics including hasmiR-107 (HY-R00057) and has-miR-145-5p (HY-R00282) were purchased from medChemExpress. ..

    Luciferase:

    Article Title: Endoplasmic reticulum-resident α-glucosidase II drives non-small cell lung cancer progression via regulation of secretory glycoproteins.
    Article Snippet: .. The resulting samples were subjected to WB analysis. miRNAs screening and Luciferase reporter assay. miRNA mimics were purchased from Thermo Fisher Scientific, including mirVana miRNA Mimic Negative Control #1 (catalog 4464058), hsa-miR-193a-5p (MC11786), hsa-miR-133a-3p (MC10413), and hsa-miR-483-3p (MC124780). miRNA mimics including hasmiR-107 (HY-R00057) and has-miR-145-5p (HY-R00282) were purchased from medChemExpress. ..

    Reporter Assay:

    Article Title: Endoplasmic reticulum-resident α-glucosidase II drives non-small cell lung cancer progression via regulation of secretory glycoproteins.
    Article Snippet: .. The resulting samples were subjected to WB analysis. miRNAs screening and Luciferase reporter assay. miRNA mimics were purchased from Thermo Fisher Scientific, including mirVana miRNA Mimic Negative Control #1 (catalog 4464058), hsa-miR-193a-5p (MC11786), hsa-miR-133a-3p (MC10413), and hsa-miR-483-3p (MC124780). miRNA mimics including hasmiR-107 (HY-R00057) and has-miR-145-5p (HY-R00282) were purchased from medChemExpress. ..



    Similar Products

    hasmir 107  (MedChemExpress)
    94
    MedChemExpress hasmir 107
    Hasmir 107, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/HY-R00282/hsa-miR-145-5p+mimic/pm42258751-239-41-49
    Average 94 stars, based on 1 article reviews
    hasmir 107 - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    mir 145a 5p mimics  (MedChemExpress)
    94
    MedChemExpress mir 145a 5p mimics
    CircPTPN4 functions as a molecular sponge for <t>miR‐145a‐5p.</t> A) Schematic representation of the binding site in the CircPTPN4 seed region for miR‐145a‐5p. B) FISH assays showing the location of CircPTPN4 and miR‐145a‐5p in primary BMECs. C) Quantitative RT‐PCR analyses of CircPTPN4, GAPDH, and CircPCNX RNAs pulled down by biotinylated WT miR‐145a‐5p (Bio‐miR‐145 WT) and biotinylated mutant miR‐145a‐5p (Bio‐miR‐145 Mut), respectively ( n = 5; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPTPN4 versus GAPDH; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPCNX versus CircPTPN4; p < 0.0001, Bio‐miR‐145 Mut‐pulled down CircPTPN4 versus Bio‐miR‐145 WT‐pulled down CircPTPN4). D) RT‐PCR analyses of U6, miR‐145a‐5p, and miR‐28a‐5p RNAs pulled down by CircPTPN4 and random probe, respectively ( n = 5; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus U6; p < 0.0001, CircPTPN4 probe‐pulled down miR‐28a‐5p versus miR‐145a‐5p; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus random probe‐pulled down miR‐145a‐5p). Data are presented as means ± S.E.M. Statistical analysis was performed using two‐way ANOVA followed by Tukey's test. Scale bar = 10 µm.
    Mir 145a 5p Mimics, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/HY-R00282/hsa-miR-145-5p+mimic/pmc12948252-454-1-25
    Average 94 stars, based on 1 article reviews
    mir 145a 5p mimics - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    hsa-mir-145-5p mimic  (MedChemExpress)
    94
    MedChemExpress hsa-mir-145-5p mimic
    CircPTPN4 functions as a molecular sponge for <t>miR‐145a‐5p.</t> A) Schematic representation of the binding site in the CircPTPN4 seed region for miR‐145a‐5p. B) FISH assays showing the location of CircPTPN4 and miR‐145a‐5p in primary BMECs. C) Quantitative RT‐PCR analyses of CircPTPN4, GAPDH, and CircPCNX RNAs pulled down by biotinylated WT miR‐145a‐5p (Bio‐miR‐145 WT) and biotinylated mutant miR‐145a‐5p (Bio‐miR‐145 Mut), respectively ( n = 5; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPTPN4 versus GAPDH; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPCNX versus CircPTPN4; p < 0.0001, Bio‐miR‐145 Mut‐pulled down CircPTPN4 versus Bio‐miR‐145 WT‐pulled down CircPTPN4). D) RT‐PCR analyses of U6, miR‐145a‐5p, and miR‐28a‐5p RNAs pulled down by CircPTPN4 and random probe, respectively ( n = 5; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus U6; p < 0.0001, CircPTPN4 probe‐pulled down miR‐28a‐5p versus miR‐145a‐5p; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus random probe‐pulled down miR‐145a‐5p). Data are presented as means ± S.E.M. Statistical analysis was performed using two‐way ANOVA followed by Tukey's test. Scale bar = 10 µm.
    Hsa Mir 145 5p Mimic, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/HY-R00282/hsa-miR-145-5p+mimic/custom%40hy-r00282%4041391036
    Average 94 stars, based on 1 article reviews
    hsa-mir-145-5p mimic - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    mir 145 5p mimics  (MedChemExpress)
    94
    MedChemExpress mir 145 5p mimics
    CircPTPN4 functions as a molecular sponge for <t>miR‐145a‐5p.</t> A) Schematic representation of the binding site in the CircPTPN4 seed region for miR‐145a‐5p. B) FISH assays showing the location of CircPTPN4 and miR‐145a‐5p in primary BMECs. C) Quantitative RT‐PCR analyses of CircPTPN4, GAPDH, and CircPCNX RNAs pulled down by biotinylated WT miR‐145a‐5p (Bio‐miR‐145 WT) and biotinylated mutant miR‐145a‐5p (Bio‐miR‐145 Mut), respectively ( n = 5; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPTPN4 versus GAPDH; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPCNX versus CircPTPN4; p < 0.0001, Bio‐miR‐145 Mut‐pulled down CircPTPN4 versus Bio‐miR‐145 WT‐pulled down CircPTPN4). D) RT‐PCR analyses of U6, miR‐145a‐5p, and miR‐28a‐5p RNAs pulled down by CircPTPN4 and random probe, respectively ( n = 5; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus U6; p < 0.0001, CircPTPN4 probe‐pulled down miR‐28a‐5p versus miR‐145a‐5p; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus random probe‐pulled down miR‐145a‐5p). Data are presented as means ± S.E.M. Statistical analysis was performed using two‐way ANOVA followed by Tukey's test. Scale bar = 10 µm.
    Mir 145 5p Mimics, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/HY-R00282/hsa-miR-145-5p+mimic/pm41035003-141-16-32
    Average 94 stars, based on 1 article reviews
    mir 145 5p mimics - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    CircPTPN4 functions as a molecular sponge for miR‐145a‐5p. A) Schematic representation of the binding site in the CircPTPN4 seed region for miR‐145a‐5p. B) FISH assays showing the location of CircPTPN4 and miR‐145a‐5p in primary BMECs. C) Quantitative RT‐PCR analyses of CircPTPN4, GAPDH, and CircPCNX RNAs pulled down by biotinylated WT miR‐145a‐5p (Bio‐miR‐145 WT) and biotinylated mutant miR‐145a‐5p (Bio‐miR‐145 Mut), respectively ( n = 5; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPTPN4 versus GAPDH; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPCNX versus CircPTPN4; p < 0.0001, Bio‐miR‐145 Mut‐pulled down CircPTPN4 versus Bio‐miR‐145 WT‐pulled down CircPTPN4). D) RT‐PCR analyses of U6, miR‐145a‐5p, and miR‐28a‐5p RNAs pulled down by CircPTPN4 and random probe, respectively ( n = 5; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus U6; p < 0.0001, CircPTPN4 probe‐pulled down miR‐28a‐5p versus miR‐145a‐5p; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus random probe‐pulled down miR‐145a‐5p). Data are presented as means ± S.E.M. Statistical analysis was performed using two‐way ANOVA followed by Tukey's test. Scale bar = 10 µm.

    Journal: Advanced Science

    Article Title: Circular RNA PTPN4 Contributes to Blood‐Brain Barrier Disruption during Early Epileptogenesis

    doi: 10.1002/advs.202502250

    Figure Lengend Snippet: CircPTPN4 functions as a molecular sponge for miR‐145a‐5p. A) Schematic representation of the binding site in the CircPTPN4 seed region for miR‐145a‐5p. B) FISH assays showing the location of CircPTPN4 and miR‐145a‐5p in primary BMECs. C) Quantitative RT‐PCR analyses of CircPTPN4, GAPDH, and CircPCNX RNAs pulled down by biotinylated WT miR‐145a‐5p (Bio‐miR‐145 WT) and biotinylated mutant miR‐145a‐5p (Bio‐miR‐145 Mut), respectively ( n = 5; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPTPN4 versus GAPDH; p < 0.0001, Bio‐miR‐145 WT‐pulled down CircPCNX versus CircPTPN4; p < 0.0001, Bio‐miR‐145 Mut‐pulled down CircPTPN4 versus Bio‐miR‐145 WT‐pulled down CircPTPN4). D) RT‐PCR analyses of U6, miR‐145a‐5p, and miR‐28a‐5p RNAs pulled down by CircPTPN4 and random probe, respectively ( n = 5; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus U6; p < 0.0001, CircPTPN4 probe‐pulled down miR‐28a‐5p versus miR‐145a‐5p; p < 0.0001, CircPTPN4 probe‐pulled down miR‐145a‐5p versus random probe‐pulled down miR‐145a‐5p). Data are presented as means ± S.E.M. Statistical analysis was performed using two‐way ANOVA followed by Tukey's test. Scale bar = 10 µm.

    Article Snippet: The miR‐145a‐5p mimics (HY‐ R00282 ), miRNA mimics negative Control (HY‐ R04602 ), miR‐145a‐5p inhibitor (HY‐RI00282), and miRNA inhibitor negative Control (HY‐RI04602) were purchased from Med Chem Express (MCE).

    Techniques: Binding Assay, Quantitative RT-PCR, Mutagenesis, Reverse Transcription Polymerase Chain Reaction

    CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression via miR‐145a‐5p sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.

    Journal: Advanced Science

    Article Title: Circular RNA PTPN4 Contributes to Blood‐Brain Barrier Disruption during Early Epileptogenesis

    doi: 10.1002/advs.202502250

    Figure Lengend Snippet: CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression via miR‐145a‐5p sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.

    Article Snippet: The miR‐145a‐5p mimics (HY‐ R00282 ), miRNA mimics negative Control (HY‐ R04602 ), miR‐145a‐5p inhibitor (HY‐RI00282), and miRNA inhibitor negative Control (HY‐RI04602) were purchased from Med Chem Express (MCE).

    Techniques: Expressing, Quantitative RT-PCR, Cell Culture, Control, Transduction, shRNA, Western Blot, Infection, Immunofluorescence, Staining, Permeability, Transfection